New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
HIGHER: Semtech (SMTC), up 3.4% after Bloomberg says that the Infineon (IFNNY) deal positions Intersil (ISIL) and Semtech for good fortune... Auxilium (AUXL), up 3.8% after announcing positive data from Phase 2a study of CCH with cellulite. DOWN AFTER EARNINGS: Sears (SHLD), down 2.6%... Kirkland's (KIRK), down 9.4%... Stage Stores (SSI), down 7%... (WUBA), down 8.8%. ALSO LOWER: Guess (GES), down 4.2% after disclosing resignation of Chief Design Officer... Medley Capital (MCC), down 2.5% after filing to sell 5M shares of common stock... Kindred Biosciences (KIN), down 28.1% after reporting that the company's pivotal field study of CereKin did not meet its primary endpoint... Ampio (AMPE), down 18.5% after delaying data analysis of STEP Study due to temperature deviations...
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 19, 2015
06:37 EDTSSIStage Stores cuts FY15 adjusted EPS to 70c-80c from $1.05-$1.15, consensus $1.00
The company expects continued challenges of stores located in geographies pressured by oil and gas and a devalued peso.
06:36 EDTKIRKKirkland's reports Q3 SSS up 1.8%
Subscribe for More Information
06:35 EDTSSIStage Stores: Q3 negatively impacted oil and gas pressure, devalued peso
06:35 EDTKIRKKirkland's reports Q3 EPS (2c), consensus 4c
Subscribe for More Information
06:35 EDTSSIStage Stores reports Q3 adjusted EPS (29c), consensus (19c)
Subscribe for More Information
November 18, 2015
19:15 EDTSMTCOn The Fly: After Hours Movers
UP AFTER EARNINGS: Keurig Green Mountain (GMCR), up 16.3%... (CRM), up 5.2%... SINA (SINA), up 2.3%... NetApp (NTAP), up marginally. ALSO HIGHER: KaloBios (KBIO), up 721.3% after the disclosure of purchases by Martin Shkreli and Anthion Partners... Vitae Pharmaceuticals (VTAE), up 23.3% after reporting top-line results from its Phase 1 trial of VTP-43742... DOWN AFTER EARNINGS: Semtech (SMTC), down 8.5% after reporting quarterly results. ALSO LOWER: Sunedison (SUNE), down 10.8% after Reuters reports that Blackstone is not interested in SunEdison investment.
16:33 EDTSMTCSemtech sees Q4 adjusted EPS 14c-18c, consensus 24c
Subscribe for More Information
16:32 EDTSMTCSemtech reports Q3 adjusted EPS 19c, consensus 24c
Subscribe for More Information
09:13 EDTAMPEAmpio to host conference call
Conference call to discuss Ampio's distribution to its existing stockholders of shares of common stock of Aytu BioScience, Inc, as well as Aytu's current business plans will be held on November 19 at 4:15 pm. Webcast Link
November 17, 2015
10:00 EDTKINOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Airgas (ARG) downgraded on valuation at KeyBanc... BHP Billiton (BHP) downgraded to Neutral from Buy at Clarksons Platou... Chesapeake (CHK) downgraded to Neutral from Buy at Sterne Agee CRT... ChipMOS (IMOS) downgraded to Equal Weight from Overweight at Morgan Stanley... Clovis (CLVS) downgraded to Neutral from Conviction Buy at Goldman... Cooper Companies (COO) downgraded to Market Perform from Outperform at Wells Fargo... Five Below (FIVE) downgraded to Neutral from Buy at Sterne Agee CRT... Grainger (GWW) downgraded to Underweight from Neutral at Atlantic Equities... Hess Corp. (HES) downgraded to Perform from Outperform at Oppenheimer... J Sainsbury (JSAIY) downgraded to Neutral from Buy at Citi... Kindred Biosciences (KIN) downgraded to Market Perform from Outperform at BMO Capital... Leju (LEJU) downgraded to Neutral from Buy at BofA/Merrill... Lombard Medical (EVAR) downgraded to Equal Weight from Overweight at Barclays... Osiris (OSIR) downgraded to Sell from Hold at Brean Capital... Polaris Industries (PII) downgraded on anemic ORV growth at Wedbush... SQM (SQM) downgraded to Hold from Buy at HSBC... Southwestern Energy (SWN) downgraded to Underperform from Neutral at Sterne Agee CRT... Starwood (HOT) downgraded to Outperform from Buy at CLSA... Urban Outfitters (URBN) downgraded to Hold from Buy at Cantor... WM Morrison (MRWSY) downgraded to Sell from Neutral at Citi... adidas (ADDDY) downgraded to Sector Perform from Outperform at RBC Capital... athenahealth (ATHN) downgraded to Underweight from Equal Weight at Barclays.
08:54 EDTIFNNYMaxim could be bidder for Fairchild, says Citi
Citi analyst Atif Malik views Maxim Integrated (MXIM) as a potential acquirer Fairchild Semiconductor (FCS). Bloomberg on October 13 reported that Fairchild was seeking advice for a potential sale, and listed potential acquirers as STMicroelectronics (STM), Infineon (IFNNY) and ON Semiconductor (ON). Bids from STM and ON seem unlikely, but Infineon and Maxim could be potential acquirers of Fairchild, Malik tells investors in a research note. In a bull case scenario, Fairchild's buyout value could reach $25 per share, the analyst contends. Fairchild closed yesterday at $17.76. Malik's peer at Citi, analyst Christopher Danely, argued today in research note that Maxim Integrated (MXIM) is unlikely to get acquired despite reports of interest from Analog Devices (ADI) and Texas Instruments (TXN). Danely views Xilinx (XLNX) as a potential takeout target, potentially for Qualcomm (QCOM).
08:33 EDTAMPEAmpio to distribute shares of Aytu BioSciences to its stockholders
Ampio Pharmaceuticals announced it has established a record date of December 1 for its previously announced distribution to its stockholders of its shares of Common Stock of Aytu BioSciences. Ampio will distribute one share of Aytu common stock for every five shares of Ampio Common Stock owned as of the record date. This distribution will constitute over 70% of the Aytu shares outstanding at this time and approximately 90% of the Aytu shares owned by Ampio. The distribution date is expected to be January 4, 2016.
08:31 EDTKINKindred downgraded on data miss, execution, weak outlook at BMO Capital
As noted earlier, BMO Capital downgraded Kindred Biosciences to Market Perform from Outperform. After the pivotal field study of company's SentiKind, for post-operative pain in dogs, did not meet its primary endpoint, BMO Capital downgraded the stock based on concerns about the company's execution and low expectations for the rest of the company's pipeline. Target to $5 from $14.
07:47 EDTMCCWells Fargo to hold a forum
Subscribe for More Information
07:03 EDTKINKindred Biosciences downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
November 16, 2015
11:35 EDTSHLDDillard's sinks to 52-week low after joining chorus of 'disappointed' retailers
Shares of Dillard's (DDS), a retailer of fashion apparel, cosmetics and home furnishing, are falling to their worst level in a year after the company became the latest in its industry to report lower than expected third quarter results. WHAT'S NEW: This morning, Dillard's reported Q3 earnings per share of $1.19 and revenue of $1.435B, narrowly missing analysts' consensus estimates of $1.20 and $1.49B, respectively. Same-store sales for the quarter fell 4%. Total merchandise sales decreased 3% for the 13-week period ended October 31. Weaker performing categories were men's apparel and accessories and ladies' accessories and lingerie with notable weakness in home and furniture the company explained. Dillard's Chief Executive Officer, William T. Dillard, II, stated, "We are disappointed with our third quarter sales performance and in the resulting decline in profit. Share buyback remained a high priority, and we repurchased $175 million of stock under our share repurchase program." WHAT'S NOTABLE: Gross margin from retail operations improved 11 basis points of sales for the 13 weeks ended October 31 compared to the prior year third quarter. Consolidated gross margin for the 13 weeks ended October 31 declined 30 basis points of sales compared to the prior year third quarter. The disparity between retail and consolidated gross margin performance is attributable to increased revenue at CDI, which is a substantially lower margin business. Inventory increased 6% at October 31 compared to November 1, 2014. For FY15, the company expects capital expenditures of $150M. PRICE ACTION: In late morning trading, Dillard's fell $5.81, or 7.5%, to $71.79 on more than three times its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week low of $68.05. Including today's pull back, the shares have lost about 36% over the past 12 months. OTHERS TO WATCH: Other apparel, cosmetics and home furnishing retailers include Macy's (M), Kohl's (KSS), JC Penny (JCP), Sears (SHLD) and Nordstrom (JWN).
10:00 EDTSMTCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alliant Energy (LNT) upgraded to Outperform from Market Perform at Wells Fargo... AmerisourceBergen (ABC) upgraded to Equal Weight from Underweight at Morgan Stanley... Amphenol (APH) upgraded to Buy from Neutral at Goldman... CA Technologies (CA) upgraded to Neutral from Sell at Citi... Cempra (CEMP) upgraded to Overweight from Equal Weight at Morgan Stanley... Edgewell Personal Care (EPC) upgraded to Neutral from Sell at Goldman... Eli Lilly (LLY) upgraded on improved growth outlook at BMO Capital... MiMedx (MDXG) upgraded to Strong Buy from Buy at Needham... NVIDIA (NVDA) upgraded to Buy from Hold at Canaccord... New York REIT (NYRT) upgraded to Buy from Hold at Evercore ISI... Oracle (ORCL) upgraded to Conviction Buy from Buy at Goldman... Perrigo (PRGO) upgraded to Buy from Neutral at UBS... Semtech (SMTC) upgraded to Buy from Neutral at B. Riley... Tullow Oil (TUWOY) upgraded to Buy from Neutral at UBS... Wabtec (WAB) upgraded to Outperform on valuatoin at Raymond James.
08:34 EDTKINKindred Biosciences announces results from pivotal study of KIND-012
Kindred Biosciences announced positive topline results from its pivotal field study of KIND-012 for the control of pyrexia in horses. This study, KB0120, was a multicenter, randomized, blinded, placebo-controlled pivotal study that enrolled 138 horses to assess the effectiveness of KIND-012. The primary endpoint was improvement or resolution of fever (a return to normothermia at hour 6 following treatment. The success rate was approximately 75% in the KIND-012 group vs. approximately 20% in the placebo group. Based on preliminary review of the safety data, the drug appears to be well tolerated. KindredBio has already completed the in-life portion of the Target Animal Safety Study successfully and is currently preparing the Chemistry, Manufacturing, and Controls technical section of the New Animal Drug Application. The company plans to file the Effectiveness Technical Section with the data from the KIND-012 pivotal field study with FDA in Q1 2016. The company also announced today that its pivotal field study of SentiKind for the control of pain following orthopedic surgery in dogs did not meet its primary endpoint. The data are in the process of being fully analyzed to determine next steps for this program.
08:13 EDTSMTCSemtech upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
07:43 EDTSMTCSemtech volatility elevated into Q3 and outlook
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use